Paradigm Biopharmaceuticals (ASX:PAR) EPS (Basic): A$-0.10 (TTM As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
28 GF Score
Price A$0.16
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals EPS (Basic)?

Paradigm Biopharmaceuticals ASX:PAR -5.88% 28 EPS (Basic) is A$-0.10 as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Paradigm Biopharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was A$-0.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.10.

Paradigm Biopharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.10.

Paradigm Biopharmaceuticals's EPS without NRI for the six months ended in Dec. 2025 was A$-0.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.10.

During the past 3 years, the average EPS without NRI Growth Rate was 31.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Paradigm Biopharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 31.70% per year. The lowest was -47.00% per year. And the median was -20.20% per year.

Paradigm Biopharmaceuticals  (ASX:PAR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Paradigm Biopharmaceuticals EPS (Basic) Related Terms

Paradigm Biopharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals EPS (Basic) Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -0.16 -0.18 -0.20 -0.06

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.04 -0.02 -0.04 -0.06
ASX:PAR
28GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Paradigm Biopharmaceuticals's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-18.771-0)/314.501
=-0.06

Paradigm Biopharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-23.244-0)/413.829
=-0.06

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of A$-0.10 mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a EPS (Basic) of A$-0.10 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' EPS (Basic) too high?
Paradigm Biopharmaceuticals' current EPS (Basic) is A$-0.10. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' EPS (Basic) compare to VRTX and REGN?
Paradigm Biopharmaceuticals' EPS (Basic) of A$-0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current EPS (Basic) is A$-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current EPS (Basic) of A$-0.10. The current EPS (Basic) is A$-0.10. Paradigm Biopharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current EPS (Basic) is A$-0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
28GF Score

Get the complete analysis for ASX:PAR

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price